J. Jay Zhang, MD, PhD

Mehmet Altan, MD

Edwin Ostrin, MD, PhD

Review

Discuss

Explore

Epidemiology, Screening, and Staging of Lung Cancer

Steven Lin, MD, PhD

Boris Sepesi, MD

Treatment of Resectable and Unresectable Stage III NSCLC and LS-SCLC

Carl Gay, MD, PhD

Xiuning Le, MD, PhD

Treatment of Metastatic NSCLC and ES-SCLC

Disparities in Cancer Care

Global Oncology

Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

Oncology Business Management

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

CAR T-cell Therapy

COVID-19

Pancreatic Cancer

Hepatocellular Carcinoma

Gastric Cancer

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Nursing News

Pediatric Oncology

Sarcomas/TGCT

Supportive Care

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority  

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma. 

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Revisit Every OncLive On Air Episode from March 2024

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Watch Leading Oncology Specialists Discuss The Current Lung Cancer Landscape

Expert Panel

Program Objectives